These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Specific protection of folate reductase against chemical and proteolytic inactivation. Hakala MT; Suolinna EM Mol Pharmacol; 1966 Sep; 2(5):465-80. PubMed ID: 6008166 [No Abstract] [Full Text] [Related]
10. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases. Gangjee A; Elzein E; Queener SF; McGuire JJ J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874 [TBL] [Abstract][Full Text] [Related]
11. The role of tryptophan-48 in catalysis and binding of inhibitors of Plasmodium falciparum dihydrofolate reductase. Kamchonwongpaisan S; Vanichtanankul J; Taweechai S; Chitnumsub P; Yuthavong Y Int J Parasitol; 2007 Jun; 37(7):787-93. PubMed ID: 17320089 [TBL] [Abstract][Full Text] [Related]
12. [Method of labelled inhibitors and its applications]. Przegl Lek; 1972; 29(7):663-9. PubMed ID: 4627387 [No Abstract] [Full Text] [Related]
13. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577 [TBL] [Abstract][Full Text] [Related]
14. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. Rosowsky A; Forsch RA; Queener SF J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Oefner C; Parisi S; Schulz H; Lociuro S; Dale GE Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):751-7. PubMed ID: 19622858 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of dihydrofolic acid reductase in the therapy of infectious diseases. Hitchings GH Bibl Nutr Dieta; 1966; 8():226-37. PubMed ID: 5331137 [No Abstract] [Full Text] [Related]
17. Models for the binding of methotrexate to Escherichia coli dihydrofolate reductase: direct effect of carboxylate of aspartic acid 27 upon ultraviolet spectrum of methotrexate. Schlegel HB; Poe M; Hoogsteen K Mol Pharmacol; 1981 Jul; 20(1):154-8. PubMed ID: 7027022 [No Abstract] [Full Text] [Related]
18. Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Itoh K; Yamamura M; Takasaki W; Sasaki T; Masubuchi A; Tanaka Y Biopharm Drug Dispos; 2006 Apr; 27(3):133-9. PubMed ID: 16400710 [TBL] [Abstract][Full Text] [Related]
19. Recent concepts on the mechanism of action of methotrexate. White JC Cancer Treat Rep; 1981; 65 Suppl 1():3-12. PubMed ID: 7326663 [No Abstract] [Full Text] [Related]